EFFICACY and SAFETY of TOLEBRUTINIB VERSUS PLACEBO in NON-RELAPSING SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: RESULTS from the PHASE 3 HERCULES TRIAL

Authors
Category Primary study
Conference54th Annual Conference of the Italian Society of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: 1f74e27cbed4eae5a205f64eea0f97f3d27c49c3
First added on: Jan 10, 2026